Viva Biotech Holdings

As of December 31, 2025, Viva Biotech Holdings carries a market capitalization of 3.80B, placing it among publicly traded companies globally. Its enterprise value stands at 4.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Viva Biotech Holdings's next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, Viva Biotech Holdings has 2.11B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Viva Biotech Holdings maintains a current ratio of 1.51, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Viva Biotech Holdings's stock has declined approximately 46.67% over the past 52 weeks. The 50-day moving average sits at 1.44, while the 200-day moving average is 1.65.

As of December 31, 2025, Viva Biotech Holdings holds 1.21B in cash and equivalents against 1.48B in total debt, resulting in a net debt position of 235.91M. Total book value stands at 4.45B, with working capital of 797.97M providing operational flexibility.